VasQ™ External Support Demonstrates Significant Improvement in Fistula Usability in the Newly Published Multi-Center Randomized-Controlled Study

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

August 26, 2019

Laminate Medical Technologies (Laminate) has announced that the American Journal of Kidney Disease has published the first multi-center, the randomized-controlled study of the VasQ External Support for newly created arteriovenous fistulas in hemodialysis patients. Arteriovenous fistulas are the standard of care for the delivery of life-sustaining hemodialysis but also carry the highest rate of failure to develop into functional dialysis accesses. The results of the newly published study demonstrate a significant improvement in fistulas becoming functional with VasQ as compared to the standard of care.

The randomized-controlled study was designed to evaluate the safety and efficacy of VasQ in improving the Short and Mid-term outcomes of arteriovenous fistulas for hemodialysis versus the standard of care. The study enrolled 40 patients randomized 1:1 and followed for 6 months. The study was conducted at Guy’s and St Thomas’ NHS Foundation Trust (London, UK); Southmead Hospital – NHS (North Bristol, UK); St. George’s University Hospitals Foundation Trust (London, UK) ; and Sheba Medical Center (Ramat Gan, Israel).

The outcomes demonstrated significant improvement in functional patency with increased intra-luminal vein diameters in the cannulation segment (a key factor to enable good fistula function) at 3-months post fistula creation. Conversely, stenosis (the leading cause of fistula failure) occurred in 15% of VasQ patients as opposed to 50% of control (P = .04). The end result was 100% of VasQ patients who required hemodialysis during the 6-month study period received it via their fistula as compared to 56% of patients in the control patients (P = .01). No safety issues were detected when comparing patients implanted with VasQ as compared to the control.

Principal investigator Dr. Nikolaos Karydis of Guy’s and St Thomas’ said,” Rarely do you observe such a stark difference in outcomes between new technology and the standard of care in dialysis access, a notoriously challenging patient population. The results suggest that VasQ has the potential to dramatically improve our global fistula outcomes for the betterment of our patients. If physician can consistently achieve functional patency as demonstrated in this study, we may avoid repeat interventions and prolonged exposure of patients to the high mortality risks of alternative therapies such as central venous catheters.”

Laminate CEO Tammy Gilon stated, “The results of this randomized-controlled study are very encouraging and an important step to validating the benefits of external support for the application in dialysis patients worldwide. We are grateful to the investigators in our studies for leading the way in changing how fistulas are created.”

 

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.